Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biological preparation and preparation method for preventing and controlling human respiratory syncytial virus infection

A technology of biological agents and syncytial virus, applied in antiviral agents, respiratory diseases, drug combinations, etc.

Active Publication Date: 2017-10-24
SHANXI JINBO BIO PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there is currently no effective drug to prevent RSV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological preparation and preparation method for preventing and controlling human respiratory syncytial virus infection
  • Biological preparation and preparation method for preventing and controlling human respiratory syncytial virus infection
  • Biological preparation and preparation method for preventing and controlling human respiratory syncytial virus infection

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0082] A preparation method of a biological preparation for preventing and controlling human respiratory syncytial virus infection, taking HSA as an example, purchasing human serum albumin; using active acid anhydride to acid anhydride the purchased protein, and repurifying the active protein after dialysis; including the following steps :

[0083] (1) Dissolve maleic anhydride (ML) in DMSO to a saturated concentration;

[0084] (2) Human serum albumin (HSA) was dissolved in 0.1M sodium phosphate solution at pH 8.5 to obtain a protein solution with a final protein concentration of 20 mg / mL;

[0085] (3) Add the ML solution to the protein solution several times, mix well after each addition, and adjust the pH to 8.5, the final concentration of the acid anhydride in the reaction system is 60mM;

[0086] (4) Under the condition of temperature of 25°C, let stand for 1 hour, then dialyze the PBS solution with pH 7.4 at 4°C. Then use a 0.45 μM microporous membrane to filter and st...

experiment example 2

[0089] A preparation method of a biological agent for preventing and controlling human respiratory syncytial virus infection, comprising the following steps:

[0090] (1) Dissolving derivatives of maleic anhydride in DMSO to obtain a saturated anhydride solution;

[0091] (2) Dissolve chicken serum albumin OVA in 0.1 M sodium phosphate solution at pH 8 to obtain a protein solution with a final protein concentration of 20 mg / mL;

[0092] (3) Divide the above ML solution into five equal parts, add it to the protein solution every 12 minutes, mix well, adjust the pH to 8 with 1M NaOH, and the final concentration of acid anhydride in the reaction system is 40mM;

[0093] (4) Under the condition of temperature of 20°C, let it stand for 1 hour, then dialyze the PBS solution with pH 7 at 4°C overnight. Then use a 0.45 μM microporous membrane to filter and sterilize, store at 4°C, and then make ointment according to the existing method.

[0094] In the biological preparation prepare...

experiment example 3

[0096] A preparation method of a biological agent for preventing and controlling human respiratory syncytial virus infection, comprising the following steps:

[0097] (1) Dissolve maleic anhydride (ML) in DMSO to a saturated concentration;

[0098] (2) Dissolve the stable protein mainly isolated and purified β-lactoglobulin (β-LG) from milk products in 0.1 M sodium phosphate solution at pH 9 to obtain a protein solution with a final protein concentration of 20 mg / mL ;

[0099] (3) Divide the above ML solution into five equal parts, add it to the protein solution every 12 minutes, mix well, adjust the pH to 9 with 1M NaOH, and the final concentration of acid anhydride in the reaction system is 50mM;

[0100] (4) Under the condition of temperature of 30°C, let it stand for 1 hour, then dialyze the PBS solution with pH 8 at 4°C overnight. Then use a 0.45 μM microporous membrane to filter and sterilize, store at 4°C, and then make a gel according to the existing method.

[0101...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel antiviral biological agent in the field of medical technology, in particular to a biological agent for preventing and controlling human respiratory syncytial virus infection and a preparation method. The present invention is a globulin viroid entry / fusion inhibitor. Its role is in the first stage of virus invasion of target cells, blocking the infection of the virus to the cells, so as to achieve the effect of preventing and controlling the virus. A reactive anhydride is used to modify positively charged amino acids on the surface of an isolated and purified protein, thereby enabling it to block the entry and infection of target cells by human respiratory syncytial virus RSV.

Description

technical field [0001] The invention relates to a novel antiviral biological agent in the field of medical technology, in particular to a biological agent for preventing and controlling human respiratory syncytial virus infection and a preparation method. Background technique [0002] Respiratory syncytial virus Respiratory Syncytial Virus (RSV) is an enveloped non-segmented negative-strand RNA virus that was discovered in 1956. It belongs to the Paramyxoviridae family, Pneumovirus genus. The RSV genome is 15kb long and expresses 11 proteins, including 3 transmembrane proteins, F, G and SH, 2 non-glycosylated matrix proteins M and M2, 3 capsid proteins N, P, L and 2 nonstructural proteins NS1 and NS2. Among them, G protein and F protein are involved in the entry and membrane fusion process of respiratory syncytial virus (RSV). Moreover, G protein and F protein are also the main epitopes for inducing antibodies. The G protein is highly variable and highly glycosylated, wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/38A61K38/00A61K47/54A61P31/14A61P11/00
Inventor 姜世勃陆路孙志武王茜杨霞
Owner SHANXI JINBO BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com